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 ABSTRACT 
The 5-HT2CR agonist lorcaserin, clinically approved for the treatment of obesity, causes important 
side effects mainly related to subtype selectivity. In the search for 5-HT2CR allosteric modulators as 
safer anti-obesity drugs, a chemical library from Vivia Biotech was screened using ExviTech® platform. 
Structural modifications of identified hit VA240 in synthesized analogues 6-41 afforded compound 11 
(N-[(1-benzyl-1H-indol-3-yl)methyl]pyridin-3-amine, VA012), which exhibited dose-dependent 
enhancement of serotonin efficacy, no significant off-target activities, and low binding competition with 
serotonin or other orthosteric ligands. PAM 11 was very active in feeding inhibition in rodents, an effect 
that was not related to the activation of 5-HT2AR. A combination of 11 with the SSRI sertraline 
increased the anorectic effect. Subchronic administration of 11 reduced food intake and body weight 
gain without causing CNS-related malaise. The behaviour of compound 11 identified in this work 
supports the interest of a serotonin 5-HT2CR PAM as a promising therapeutic approach for obesity. 
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 INTRODUCTION 
Obesity, defined as having a body mass index (weight [kg]/height [m2]) equal to or greater than 30 
kg/m2, is a major global health issue affecting nearly one billion adults worldwide and this number 
continues to rise.1 Obesity is a major risk factor for chronic diseases, such as diabetes, cardiovascular 
pathology, and certain cancers.2 Hence, it is widely believed that obesity will become one of the leading 
causes of morbidity and mortality for this and future generations. Although a number of strategies have 
been used to tackle obesity, most of the marketed medicines have been withdrawn mainly due to safety 
issues,3 including CNS-related adverse effects, and the pharmaceutical options available to obese 
patients are currently limited.4, 5 Therefore, there is a major need for new agents that can provide a safe 
and effective mechanism for inducing weight loss. 
Among the variety of pharmacological approaches that can be used to control body weight, the 
serotonin (5-hydroxytryptamine, 5-HT) system has long been known to be involved in the modulation of 
food intake.6-8 Accordingly, classical anti-obesity medicines such as sibutramine (1) and 
(dex)fenfluramine (2) (Figure 1A) act by increasing the level of serotonin.6, 7 The current classification 
of the serotonin receptor family, which has essentially remained unchanged since 1994,9-11 includes 
fourteen receptor subtypes classified into seven major classes (5-HT1-7). The 5-HT2 class comprises 
three GPCR members (5-HT2A, 5-HT2B, 5-HT2C) characterized by close sequence homology and 
coupling primarily via Gq proteins to intracellular signalling pathways such as phospholipase C and 
phospholipase A.12 In particular, serotonin 2C receptors are predominantly expressed in the CNS where 
they are widely distributed in different brain regions. There is substantial evidence supporting that their 
modulation may offer therapeutic benefit in various pathological conditions, including schizophrenia, 
substance addiction, and obesity.13-15 In this regard, the 5-HT2C receptor (5-HT2CR) is critical for the 
anorectic effect of serotoninergic activation,7, 13 and the satiating effects of 2 have thus been 
demonstrated to be attenuated in 5-HT2CR knockout mice, as well as by selective 5-HT2CR 
antagonists.16, 17 
Page 3 of 32
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Stimulation of 5-HT2CRs is the most advanced approach towards serotonin mediated control of food 
intake and associated reduction in body weight, and multiple research efforts have identified several 
promising 5-HT2CR ligands.18-20 In 2012, the 5-HT2CR agonist lorcaserin (3, Figure 1B) was approved 
by the FDA as a first-in-class anti-obesity drug.21, 22 Therefore, the activation of 5-HT2CRs has been 
validated in the search of therapeutic strategies for the treatment of obesity. However, selectivity is 
critical because of the detrimental effects of 5-HT2A and 5-HT2B receptor activation that are respectively 
associated with potential hallucinogenic effects23 and cardiac valvulopathy.12, 24 Indeed, increased risk of 
cardiovascular and cardiopulmonary diseases has led to the withdrawal of non-selective serotoninergic 
drugs 1 and 2 from the EU and the USA markets, respectively,25, 26 and certain restrictions apply to the 
use of compound 3 as its moderate 5-HT2BR activity might induce major cardiac side effects.27 Clearly, 
further efficacy and safety data are needed to prove the clinical utility of 5-HT2CR ligands as anti-obesity 
agents. 
In this context, the development of 5-HT2CR agonists with better selectivity profiles for this 
worldwide disease would be of great value. This represents a significant challenge, as the molecular 
determinants involved in ligand recognition by 5-HT2R subtypes are highly conserved.11 More 
opportunities may emerge from targeting an allosteric binding site as opposed to the orthosteric site of 
the 5-HT2CR protein. Positive allosteric modulators (PAMs) should elicit a more physiologically 
relevant enhancement of target function compared to an orthosteric agonist.28-31 To date, PNU-69176E 
(4, Figure 1B) is the only 5-HT2CR PAM described, which was identified via screening of a chemical 
library of Pharmacia (now Pfizer).32, 33 A derivative of this modulator (CYD-1-79, undisclosed structure) 
has recently been reported to potentiate 5-HT2CR signalling in vivo in a drug discrimination assay,34 
though no anti-obesity properties have been described to our knowledge. 
In the present work, we contribute to the quest for selectively acting 5-HT2CR modulators. In the 
screening of a chemical library from Vivia Biotech company using a proprietary platform, compound 5 
(VA240, Figure 2) was identified and validated as a moderate PAM of the 5-HT2CR. Further structural 
modification in synthetic analogues 6-41 (Figure 2) has led to compound 11 (VA012, N-[(1-benzyl-1H-
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 indol-3-yl)methyl]pyridin-3-amine) with enhanced allosteric efficacy that was found to be very active in 
feeding models in rodents, reducing both food intake and body weight gain without inducing CNS-
related malaise. 
 
RESULTS AND DISCUSSION 
 
Hit identification: high-throughput screening. The proprietary ExviTech® platform developed 
by Vivia Biotech is a highly sensitive method based on flow cytometry to assess activation of GPCRs. A 
functional whole cell assay is used to access activity by measuring calcium mobilization in response to 
receptor activation. For screening, the tested compounds were added to HEK-293 cells stably expressing 
5-HT2CR, and after 10 min a 25% of the maximal effective concentration (EC25) of serotonin was added. 
The resulting percentage of cells that respond was then determined. The response for each well (i.e., 
compound) was compared to control receiving only an EC25 concentration of serotonin, any response 
above this level indicating a potential modulator. Specificity was simultaneously analyzed by screening 
cell lines expressing close family members –5-HT2A and 5-HT2B subtypes– using multi-parametric flow 
cytometry and cell tracking dyes. A Vivia Biotech chemical library of approximately 1600 compounds 
was screened on ExviTech platform at a concentration of 10 µM (Figure 2). Three compounds enhanced 
in ~20% the effect produced by serotonin in cells expressing the 5-HT2CR, whereas no potentiation of 
serotonin effect was observed for 5-HT2A and 5-HT2B receptors. 
The three putative modulators identified in the ExviTech platform were validated for their ability to 
stimulate the 5-HT2CR in a functional assay by determining inositol monophosphate (IP) levels in cells, 
a well characterized signalling pathway of receptor activation. Biological analyses were conducted in 
HeLa cells stably expressing physiological levels of the human 5-HT2CR. Cells were treated with a fixed 
concentration of the tested compounds (10 µM) and increasing concentrations of serotonin. The 
accumulation of IP was quantified by homogeneous time-resolved fluorescence energy transfer (HTRF). 
A 5-HT dose-response curve was obtained in the presence of each compound, and potentiation of the 5-
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 HT maximal effect (Emax) was measured. Using this assay compound 5 (Figure 2) enhanced the IP 
release induced by 5-HT, with a 20% potentiation of 5-HT Emax, which supports the allosteric activity at 
the 5-HT2CR. Hence, 5 was selected as a starting hit for the search of new synthetic modulators of the 5-
HT2CR with enhanced allosteric efficacy. 
Optimization of compound 5. Starting from the validated hit 5, two series of analogues 6-14 and 
15-41 (Figure 2 and Tables 1, 2) were generated by modification of the pyrimidine or the phenyl ring 
attached to the indole scaffold, respectively, to examine the effect on functional activity and allosteric 
modulation at the 5-HT2CR. In compounds 6-14 (Table 1), the phenyl ring was maintained and different 
nitrogen-containing heterocycles were introduced. These compounds were synthesized by reductive 
amination starting from 1-benzyl-1H-indole-3-carbaldehyde (Scheme 1). Derivatives 6-9 and 13 were 
prepared via one-pot reaction of the aldehyde with the corresponding pyrimidin-, pyrazin-, pyridazin-, or 
pyridinamine in 1,2-dichloroethane using sodium triacetoxyborohydride as reducing agent. For 
compounds 10-12 and 14, a two-step procedure was carried out. In this case, condensation of 1-benzyl-
1H-indole-3-carbaldehyde with pyridazin-4-amine or the appropriate pyridinamine, catalyzed by p-
toluenesulfonic acid in refluxing toluene, afforded the corresponding imine, which was isolated and 
subsequently reduced with sodium borohydride in methanol. 
Synthesized compounds 6-14 were assessed for their effect on 5-HT-induced IP release in 5-HT2CR-
HeLa cells. From the data in Table 1, most compounds resulted inactive though in general pyridyl 
derivatives showed potentiation of the endogenous agonist effect. In particular, 3-pyridyl analogue 11 
exhibited the highest potentiation (35% at 10 µM). 
We next approached the synthesis of the second series of proposed compounds 15-41, where the 3-
pyridyl moiety of compound 11 was maintained as N-heterocycle and the phenyl ring was modified. In 
analogues 15-37 (Table 2) substituents of different size and electronic effects (F, Cl, Br, Me, OMe, CF3, 
CN) were introduced in the benzene ring. These compounds were obtained by N-alkylation of the indole 
intermediate 42 with the appropriate benzyl bromide derivative using sodium hydride as base (Scheme 
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 2). Intermediate 42 was prepared by reductive amination of 1H-indole-3-carbaldehyde with pyridin-3-
amine, following the two-step procedure above described. 
In addition, replacement of the benzene ring with a pyridine was considered in compounds 38-40, as 
well as that with a cyclopropane ring in compound 41 (Table 2) to explore the requirement of 
aromaticity at the 1-position of the indole scaffold. In the case of pyridine-containing derivatives 38-40, 
alkylation reaction of 42 with the corresponding (bromomethyl)pyridines failed, and an alternative N-
alkylation-reductive amination sequence was followed (Scheme 2). Thus, treatment of 1H-indole-3-
carbaldehyde with the appropriate bromide derivative in the presence of cesium carbonate yielded 
intermediates 43-45, which after reductive amination with pyridin-3-amine afforded final compounds 
38-40. Similarly, cyclopropyl derivative 41 was synthesized by reductive amination of intermediate 46, 
obtained by alkylation of 1H-indole-3-carbaldehyde with (bromomethyl)cyclopropane using sodium 
hydride as base (Scheme 2). 
The new set of compounds 15-41 was tested in the IP functional assay and the data are shown in 
Table 2. No substantial improvement of the allosteric potentiation was observed for any of the aryl 
derivatives, which exhibited lower values than unsubstituted analogue 11. The presence of heterocyclic 
pyridine or non-aromatic cyclopropane in analogues 38-41 was also less favourable than that of a phenyl 
ring (Table 2). Hence, compound 11 was selected for further pharmacological characterization as an 
allosteric modulator of the 5-HT2CR. 
In vitro characterization of compound 11. Compound 11 was evaluated in the 5-HT-induced IP 
assay at different concentrations in CHO cells stably expressing 5-HT2CR. As shown in Figure 3A, 
results revealed an increase of 5-HT Emax, reaching 35% of potentiation at 10 µM. It should be noted that 
a lower concentration of 1 µM enhanced the maximal effect of 5-HT by 28%. In the concentration-
response curve of the compound over 5-HT EC70, a dose-dependent potentiation of 5-HT effect was 
obtained, with a high potency for compound 11 (EC50 = 16±2 nM). The compound did not induce IP 
release in the 5-HT2CR-CHO cells in the absence of 5-HT (Figure 3B), so it does not present intrinsic 
agonist activity. Importantly, this profile for compound 11 was distinguished from that seen in 5-HT2AR-
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 CHO (Figure 3C and 3D) and 5-HT2BR-CHO (Figures 3E and 3F) cells in which neither the compound 
in the presence of 5-HT nor alone altered IP release. 
In addition to the selectivity exhibited over 5-HT2 subtypes, no significant off-target agonist or 
antagonist activities were observed in a CEREP cellular GPCR profile of the compound (no effect over 
20% at 10 µM was observed in either agonist or antagonist assays), which discarded important safety 
issues. 
In radioligand binding competition assays, 10 µM 11 showed low displacement of the endogenous 
agonist (5-HT) or other orthosteric ligands (mesulergine and clozapine), suggesting its binding to a 
different site of the receptor (Figure 3G). The moderate affinity observed for compound 11 in the 
presence of LSD may be due to the location of this orthosteric ligand close to the extracellular domain of 
the receptor, where allosteric modulators of aminergic GPCRs bind.28 This is in agreement with the 
recently reported crystal structure of the closely related 5-HT2BR bound to LSD.35 
Overall, the in vitro characterization of compound 11 proves its pharmacological profile as a 
specific and safe PAM of the 5-HT2CR, which supports the exploration of its activity in vivo. 
In vivo behaviour of the new 5-HT2CR PAM 11. Prior to the evaluation of the new 5-HT2CR 
PAM 11 in animal models, the in vivo brain permeability was studied (Figure S1). Results showed a 
ratio of concentrations of the compound in brain and plasma of 3.8 after 120 min when administered 
intraperitoneally (i.p.) at a dose of 10 mg/kg. Importantly, this ratio was constant up to 6 h. These data 
prompted us to assess the behaviour of 11 in animal models of obesity. 
In a first experiment, food intake was monitored upon acute administration of studied compound or 
the 5-HT2CR agonist 47 (WAY 161503)36 assayed as a reference compound of 5-HT2CR activation 
(Figures 4A and 4B). Both compounds induced a reduction in feeding when they were acutely 
administered at 2 mg/kg (i.p.). Agonist 47 produced a reduction in food intake that was more intense at 
the earlier times and almost vanished after 4 h (Figure 4A, dose effect F (2.80) = 51.9, P<0.01). Notably, 
the newly identified allosteric modulator 11 reduced feeding with a higher efficacy (Figure 4B, dose 
effect F (3.82) = 256, P<0.001) and with a more prolonged action (time x dose interaction F (3.82) = 
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 5.3, P<0.01), reaching almost 50% reduction after 4 h at the dose of 10 mg/kg. The effects of 11 were 
not related to the activation of serotonin 5-HT2AR, as revealed by the persistence of food intake 
inhibition despite pretreatment with the 5-HT2AR antagonist ketanserin (Figure S2A). In addition, the 
effect of 11 was not eliminated after pretreatment with the 5-HT2CR antagonist 48 (SB-242084, Figure 
S2B),37 whereas the antagonist did reduce the inhibition produced by the 5-HT2CR agonist 47 (Figure 
S2C). These results suggest no direct action of PAM 11 at the orthosteric site of the receptor. 
When compound 11 was administered in a restricted food access model, it reduced both food intake 
(Figure 4C, F (6.98) = 7.9, P<0.001) and body weight gain (Figure 4E, F (6.98) = 10.7, P<0.001). 
Similar results were observed after seven days of repeated administration of the compound in a 
continuous food access model, where both daily food intake (Figure 4D, F (6.98) = 6.2, P<0.001) and 
body weight gain (Figure 4F, F (6.98) = 3.9, P<0.01) decreased. 
In order to establish whether the new PAM induced side effects, we explored the appearance of 
hypolocomotion, anxiety and conditioned taste aversion. The compound induced hypolocomotion in the 
elevated plus maze (Figure 4G, F (2.21) = 12, P<0.01). Anxiety cannot be discarded (Figure S3A) 
although the hypolocomotion made very difficult the evaluation of this response. The hypolocomotion 
was also observed in the open field test (Figure S3B). The hypolocomotor profile of PAM 11 appears as 
a side effect that might limit its therapeutic utility at certain doses, as it has also been described for 5-
HT2CR agonists such as lorcaserin in animal models of obesity or nicotine addiction.38 On the other 
hand, administration of compound 11 (2 mg/kg, i.p.) did not result in conditioned taste aversion (Figure 
4H, treatment per saccharin interaction, F (2.58) = 26.5, P<0.01), indicating that the compound did not 
cause malaise, in contrast to LiCl used as positive control. 
As a way of demonstrating allosteric potentiation of serotonin-induced feeding suppression by 
compound 11, we tested the effects of co-administration with the selective serotonin re-uptake inhibitor 
(SSRI) sertraline. This antidepressant drug is known to induce a mild feeding suppression, as shown in 
Figure 5A (F (3.112) = 29.1, P<0.01) when administered in a wide range of doses (0.4 to 10 mg/kg). In 
this experiment, two different combinations of both compounds were used: 0.5 mg/kg 11 with 2 mg/kg 
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 sertraline (Figure 5B) and 2 mg/kg 11 with 5 mg/kg sertraline (Figure 5C). When the extracellular 
concentration of serotonin increased upon administration of sertraline, the anorectic effect of 11 was 
potentiated, as expected for a positive modulator of the receptor activity (interaction 11-sertraline F 
(9.111) = 4.6 P<0.001). This is a very remarkable action since the prevalence of depression associated to 
obesity is very high, i.e. 19% in severe obesity.39 This combination might offer a new strategy for 
feeding reduction in depressed obese people. 
 
CONCLUSIONS 
In this work we have developed compound 11 (N-[(1-benzyl-1H-indol-3-yl)methyl]pyridin-3-amine) 
as an allosteric modulator of the serotonin 5-HT2CR that exhibits enhanced efficacy dose-dependently, 
no significant off-target activities, and low competition with the endogenous agonist or other orthosteric 
ligands. The compound was found to be very active in feeding models in rodents, reducing both food 
intake and body weight gain without causing CNS-related malaise when administered subchronically. 
The effects were not related to 5-HT2AR activation and a potentiation of the anorectic action of 11 was 
observed when administered in combination with sertraline, which suggests an allosteric modulation of 
serotonin effect in vivo. These results support the interest of a 5-HT2CR PAM as a promising therapeutic 
approach for obesity. 
 
EXPERIMENTAL SECTION 
Synthesis. Unless otherwise stated, the starting materials, reagents, and solvents were purchased as 
high-grade commercial products from Sigma-Aldrich, Acros, ABCR, Fluorochem, Scharlab, or Panreac. 
Analytical thin-layer chromatography (TLC) was run on Merck silica gel plates (Kieselgel 60 F-254), 
with detection by UV light (λ = 254 nm), 5% ninhydrin solution in ethanol or 10% phosphomolybdic 
acid solution in ethanol. Unless otherwise stated, products were purified by flash chromatography using 
a VARIAN 971-FP system with cartridges of silica gel (Varian, particle size 50 µm). All compounds 
were obtained as oils, except for those whose melting points (m.p.) are indicated, which were solids. 
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 M.p. (uncorrected) were determined on a Stuart Scientific electrothermal apparatus. Infrared (IR) spectra 
were measured on a Bruker Tensor 27 instrument equipped with a Specac ATR accessory of 5200-650 
cm-1 transmission range; frequencies (ν) are expressed in cm-1. 1H-, 13C- and 19F-NMR spectra were 
recorded on a Bruker Avance 500 MHz (1H, 500 MHz; 13C, 125 MHz) or Bruker DPX 300 MHz (1H, 
300 MHz; 13C, 75 MHz; 19F, 300 MHz) instrument at room temperature (rt) at the Universidad 
Complutense de Madrid (UCM) NMR core facility. Bruker DPX 300 MHz equipment was used unless 
otherwise stated. Chemical shifts (δ) are expressed in parts per million relative to the residual solvent 
peak for 1H and 13C nucleus (CDCl3: δH = 7.26, δC = 77.16; DMSO-d6: δH = 2.50, δC = 39.52) and to 
internal (trifluoromethyl)benzene for 19F nucleus; coupling constants (J) are in hertz (Hz). The following 
abbreviations are used to describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), q 
(quartet), qt (quintet), m (multiplet), app (apparent), and br (broad). 2D NMR experiments –
homonuclear correlation spectroscopy (H,H-COSY), heteronuclear multiple quantum correlation 
(HMQC) and heteronuclear multiple bond correlation (HMBC)– of representative compounds were 
acquired to assign protons and carbons of new structures. For all final compounds, purity was 
determined by high-performance liquid chromatography (HPLC) coupled to mass spectrometry (MS) 
using an Agilent 1200LC-MSD VL instrument, and satisfactory chromatograms confirmed a purity of at 
least 95% for all tested compounds. LC separation was achieved with a SunFire C18 column (3.5 µm, 
2.1 mm x 100 mm), together with a guard column (5 µm, 4.6 mm x 12.5 mm). The mobile phase 
consisted of A (1:1 ACN/methanol) and B (5 mM NH4OH pH 7). MS analysis was performed with an 
ESI source. Spectra were acquired in positive or negative ionization mode from 80 to 800 m/z and in 
UV-mode in the wavelength range 210-400 nm. 
General procedure for one-pot reductive amination. To a suspension of 1-benzyl-1H-
indole-3-carbaldehyde (1.0 equiv) and NaBH(OAc)3 (3.0 equiv) in anhydrous 1,2-
dichloroethane (10 mL/mmol), the corresponding amino N-heterocycle (2.5 equiv) was added 
under an argon atmosphere and the reaction was refluxed for 8-15 h. After this time, the mixture 
was allowed to reach rt, and it was diluted with DCM and washed with water. The organic layer 
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 was dried over Na2SO4, filtered and concentrated. The crude was purified by flash 
chromatography (some of them were slurred with hexane afterwards) to afford the final 
compounds 6-9, 13. 
N-[(1-Benzyl-1H-indol-3-yl)methyl]pyridazin-3-amine (9). Following the general 
procedure for one-pot reductive amination, compound 9 was obtained from 1-benzyl-1H-indole-
3-carbaldehyde (390 mg, 1.66 mmol) and pyridazin-3-amine (316 mg, 3.32 mmol) as an off-
white solid (63 mg, 12%). Chromatography: DCM/methanol 96:4. M.p.: 152-153 °C. Rf: 0.27 
(DCM/methanol 95:5). IR (ATR): ν 3248 (NH), 1598, 1509, 1467 (Ar). 1H-NMR (CDCl3): δ 
4.69 (d, J = 4.4, 2H, CH2NH), 5.19 (br s, 1H, NH), 5.30 (s, 2H, NCH2), 6.35 (d, J = 5.8, 1H, H4), 
7.09-7.16 (m, 4H, H2’, H5’, H2’’, H6’’), 7.19-7.25 (m, 1H, H6’), 7.29-7.35 (m, 4H, H7’, 3CHPh), 
7.63 (d, J = 7.7, 1H, H4’), 8.16 (d, J = 4.9, 1H, H5), 8.60 (app s, 1H, H6). 13C-NMR (CDCl3): δ 
37.2 (CH2NH), 50.2 (NCH2), 110.2 (C7’), 111.5 (C3’), 119.1 (C4’), 119.9 (C5’), 122.5 (C6’), 127.0 
(C2’’, C6’’), 127.1 (C2’), 127.2 (C3a), 127.9 (C4’’), 129.0 (C3’’, C5’’), 137.0 (C7a), 137.3 (C1’’), 
155.3 (C5), 158.8 (C6), 161.8 (C3), C4 not observed. HPLC (tR, min): 17.70. MS (ESI, m/z): 
calcd. for C20H19N4 ([M + H]+), 315.2; found, 315.2. 
General procedure for two-step reductive amination. p-Toluenesulfonic acid (0.1 equiv) 
was added to a solution of 1H-indole-3-carbaldehyde, 1-benzyl-1H-indole-3-carbaldehyde or 
intermediates 43-46 (1.0 equiv) and the corresponding amino N-heterocycle (1.2 equiv) in 
anhydrous toluene (8 mL/mmol) under an argon atmosphere. The reaction mixture was refluxed 
for 1-18 h using a Dean-Stark equipment to remove water from the reaction medium. Solvent 
was concentrated off to afford the corresponding imine, which was used in the next step without 
further purification. 
NaBH4 (2.5 equiv) was added portion-wise to a 0 °C cooled solution of the previous imine in 
methanol (8 mL/mmol). The reaction was allowed to warm up to rt and stirred for 0.25-2 h. 
Then, the mixture was poured into brine, extracted with DCM (x2) and washed with water. The 
organic layer was dried over Na2SO4, filtered and concentrated. The crude was purified by flash 
Page 12 of 32
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 chromatography (some of them were slurred with hexane afterwards) to afford intermediate 42 
or final compounds 10-12, 14, 38-41. 
N-[(1-Benzyl-1H-indol-3-yl)methyl]pyridin-3-amine (11). Following the general procedure 
for two-step reductive amination, compound 11 was obtained from 1-benzyl-1H-indole-3-
carbaldehyde (500 mg, 2.12 mmol) and pyridin-3-amine (239 mg, 2.54 mmol) as a white solid 
(488 mg, 73%). Chromatography: hexane/EtOAc from 1:1 to 3:7. M.p.: 159-160 °C. Rf: 0.31 
(hexane/EtOAc 2:8). IR (ATR): ν 3398 (NH), 1585, 1471, 1332 (Ar). 1H-NMR (CDCl3): δ 3.96 
(br s, 1H, NH), 4.48 (d, J = 4.1, 2H, CH2NH), 5.30 (s, 2H, NCH2), 6.96 (ddd, J = 8.2, 2.7, 1.2, 
1H, H4), 7.08-7.33 (m, 10H, H5, 4CHindole, 5CHPh), 7.67 (d, J = 7.7, 1H, H4’), 7.99 (d, J = 4.5, 
1H, H6), 8.10 (d, J = 2.5, 1H, H2). 13C-NMR (CDCl3): δ 39.8 (CH2NH), 50.2 (NCH2), 110.1 
(C7’), 112.3 (C3’), 118.7 (C4), 119.2 (C4’), 119.8 (C5’), 122.4 (C6’), 123.8 (C5), 127.0 (C2’’,C6’’), 
127.1 (C2’), 127.4 (C3a), 127.9 (C4’’), 128.9 (C3’’, C5’’), 136.3 (C2), 137.0 (C7a), 137.4 (C1’’), 
138.9 (C6), 144.4 (C3). HPLC (tR, min): 19.67. MS (ESI, m/z): calcd. for C21H20N3 ([M + H]+), 
314.2; found, 314.4. 
General procedure for N-alkylation reaction. To a solution of 1H-indole-3-carbaldehyde or 
42 (1.0 equiv) in anhydrous DMF (15 mL/mmol) under an argon atmosphere, sodium hydride 
(60% suspension in mineral oil, 1.2 equiv) or Cs2CO3 (3.0 equiv) was added. The mixture was 
stirred at rt for 15 min and the corresponding bromoderivative (1.2 equiv) was added. The 
reaction was stirred at rt for 0.25-2 h, and then it was poured into brine and extracted with Et2O 
or DCM (x2). The combined organic layers were washed with water, dried over Na2SO4, filtered 
and concentrated. DMF was removed under high vacuum, and the residue was used in the next 
step without further purification in the case of intermediates 43-46, or purified by flash 
chromatography (some of them were slurred with hexane afterwards) to afford final compounds 
15-37. 
N-{[1-(3-Chlorobenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine (19). Following the 
general procedure for N-alkylation reaction, compound 19 was obtained from 42 (260 mg, 1.16 
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 mmol) and 1-(bromomethyl)-3-chlorobenzene (288 mg, 1.40 mmol), using sodium hydride, as a 
white solid (247 mg, 61%). Chromatography: hexane/EtOAc from 7:3 to 3:7. M.p.: 136-137 °C. 
Rf: 0.26 (hexane/EtOAc 2:8). IR (ATR): ν 3398 (NH), 1588, 1481, 1466 (Ar). 1H-NMR 
(CDCl3): δ 3.99 (br s, 1H, NH), 4.50 (d, J = 2.7, 2H, CH2NH), 5.26 (s, 2H, NCH2), 6.94-6.98 (m, 
2H, H4, H6’’), 7.08-7.29 (m, 8H, H5, 4CHindole, 3CHPh), 7.67 (d, J = 7.7, 1H, H4’), 7.99 (dd, J = 
4.6, 0.8, 1H, H6), 8.11 (d, J = 2.8, 1H, H2). 13C-NMR (CDCl3): δ 39.8 (CH2NH), 49.6 (NCH2), 
110.0 (C7’), 112.8 (C3’), 118.7 (C4), 119.3 (C4’), 120.0 (C5’), 122.6 (C6’), 123.9 (C5), 125.0 (C6’’), 
126.9, 127.0 (C2’, C2’’), 127.4 (C3a), 128.1 (C5’’), 130.3 (C4’’), 134.9 (C3’’), 136.2 (C2), 136.9 
(C7a), 139.0 (C6), 139.5 (C1’’), 144.4 (C3). HPLC (tR, min): 19.77. MS (ESI, m/z): calcd. for 
C21H19ClN3, 348.1 ([M(35Cl) + H]+), 350.1 ([M(37Cl) + H]+); found 348.2, 350.2. 
Functional activity at 5-HT2 receptors. IP formation was measured by using the HTRF IP-
One assay kit (CisBio, France). Assays were carried out in human 5-HT2A, 5-HT2B and 5-HT2C 
receptors expressed in CHO-K1 (5-HT2A and 5-HT2B) and HeLa-K1 (5-HT2C) cell lines. Cells 
were seeded (20000 cells/well for 5-HT2A and 5-HT2C and 30000 cells/well for 5-HT2B) in a 96-
well plate in 100 µL of culture medium (DMEM, 10% FBS, 4 mM L-glutamine) and maintained 
at 37 oC in a 5% CO2 atmosphere for 24 h. After this time, medium was replaced by 50 µL of kit 
stimulation buffer and compounds (test compound and/or 5-HT) were added to the wells. Cells 
were incubated for 20 min at 37 oC and then the IP accumulation was measured by using the kit 
reagents. HTRF was quantified in an ultra-evolution multilabel reader (Tecan M1000 Genius 
Pro).  
Data were normalized to 5-HT maximum effect and non-linear regression fitting was 
performed by using Prism v2.1 (GraphPad software). 
Radioligand binding assays at 5-HT2CR. Competition radioligand binding assays were 
carried out by using four different radioligands: [3H]mesulergine, [3H]serotonin, [3H]LSD and 
[3H]clozapine. 5-HT2C-HeLa membrane suspensions (15 µg/well for [3H]mesulergine and 
[3H]LSD, 60 µg/well for [3H]serotonin and 20 µg/well for [3H]clozapine) were incubated with 
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 the test compound (10 µM) and radioligand (4 nM [3H]mesulergine, 2 nM [3H]serotonin, 2 nM 
[3H]LSD and 15 nM [3H]clozapine) in assay buffer (50 mM Tris-HCl, pH = 7.4). The incubation 
conditions were 60 min at 27 oC for [3H]mesulergine, [3H]LSD and [3H]clozapine, and 180 min 
at 4 oC for [3H]serotonin. Non-specific binding was determined in the presence of 10 µM 
mianserin. After the incubation time samples were filtered through Multiscreen FC 96-well 
plates (Millipore) and washed four times with wash buffer (50 mM Tris-HCl, pH = 6.6). 
Radioactivity was detected in a Microbeta Trilux reader (Perkin Elmer). 
In vivo experiments. For acute experiments, male Wistar rats (Charles Rivers Laboratories, 
Barcelona, Spain) weighing 200–250 g and aged 10–12 weeks at the beginning of the 
experiments were used. For subchronic experiments, male Wistar animals were made obese after 
8 weeks of treatment with a high fat diet (HFD, 60% fat diet-D12492, Brogaarden, Gentofke, 
Denmark) containing 5.24 kcal/g (20% of the metabolizable energy content was protein, 20% 
carbohydrates and 60% fat). When tested for subchronic effects of compound 11, animals had an 
average weight of 548±20 g (see Crespillo et al. for further details).40 Animals were housed in 
groups of two in a humidity- and temperature-controlled (22 °C) vivarium on a 12:12-h light-
dark cycle (lights off at 8 PM). Water and standard laboratory chow were available ad libitum 
throughout the course of the studies, unless otherwise indicated (e.g., in the diet-induced obesity 
procedure). All procedures were conducted in adherence to the European Communities Council 
Directive (86/609/ECC) and Spanish regulations (BOE 252/34367-91, 2005) for the use of 
laboratory animals. They were reviewed and approved by the Comisión de Ética e Investigación, 
Hospital Carlos Haya, Málaga (Spain). Procedures can be found in Gomez et al.41 All data are 
shown as mean±SEM of at least eight determinations per experimental group. Kolmogorov–
Smirnov normality tests indicated that all data followed a Gaussian distribution (P > 0.1), so we 
selected a parametric statistical test. Differences between the treatments and time of testing 
(along 7-day testing) were analysed by two-way ANOVA for repeated measures, followed by 
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 Bonferroni post hoc test for multiple comparisons. The level of statistical significance was set at 
P < 0.05. Details on the methodology can be found on Crespillo et al.40 
Acute feeding suppression. Adult rats were food deprived for 16 h prior to refeeding, to 
habituate the animals to the procedure. On the testing day, and after food deprivation, compound 
11 was i.p. injected at the doses of 0.5, 2 and 10 mg/kg dissolved in sterile saline. Food and 
water intake were then measured at 30, 60, 120 and 240 min after the presentation of food. The 
5-HT2CR agonist 474 (doses of 0.2 and 2 mg/kg, i.p.) was also tested for comparison of the acute 
suppression effect. In additional experiments, animals were pretreated with the inhibitor of the 
serotonin re-uptake system sertraline (doses of 0.4, 2, 5 and 10 mg/kg), the 5-HT2AR antagonist 
ketanserin (2 mg/kg) or the 5-HT2CR antagonist 48 (3 mg/kg), all purchased from Tocris 
Cookson (Bristol, UK), that were i.p. injected 30 min prior to 11, and the suppression effect was 
also analyzed. 
Repeated administration under continuous food access. To assess the subchronic (7-day 
treatment) effect of 11, free-feeding rats were injected daily with the compound (2 mg/kg, i.p.) 
or vehicle. The amount of standard laboratory chow (3.02 kcal/g with 30 kcal% proteins, 55 
kcal% carbohydrates and 15 kcal% fat) eaten (kcal/kg body weight) and the body weight gain 
(g) were registered daily. 
Repeated administration under food restriction schedule. Animals were presented with 
food for 4 h a day. Once the 4 h period was over, food was retired until the next day. When a 
stable baseline of feeding was achieved, 11 (2 mg/kg, i.p.) or vehicle were injected 30 min prior 
to food presentation, and food and water intakes were measured at the end of the 4 h period. The 
procedure was repeated for 7 consecutive days, and total food intake and body weight were 
monitored. 
Elevated plus maze. Animals naïve to the maze were manipulated for 7 days before testing. 
The day of the experiment, 30 min after the i.p. injection of 11, animals were placed in the 
centre of the maze, facing an open arm. The number of entries and the % of time spent in the 
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 exposed arms of the maze were measured. Test length was 5 min and animals were not retested 
(for details see Rodriguez de Fonseca et al. 2001).42 
Open field. Animals naïve to the open field were manipulated for 7 days before testing. The 
day of the experiment, 30 min after the injection of 11 (2 mg/kg, i.p.), animals were placed in 
the centre of the maze, and the distance walked registered through an automated procedure.42 
Test length was 10 min and animals were not retested. 
Conditioned taste aversion. Rats were deprived of water for 24 h and then accustomed to 
drinking from a graded bottle during a 30-min test period for 4 days. On day 5 water was 
replaced with a 0.1% saccharin solution, and 30 min later the animals received i.p. injections of 
vehicle, 11 (2 mg/kg) or lithium chloride (0.4 M, 7.5 mL/kg). During the following 2 days, water 
consumption was recorded over 30-min test periods. The animals were then presented with 
water or saccharin, and drinking was finally measured.42 
 
ASSOCIATED CONTENT 
Supporting Information. Supplementary Figures S1 to S3, synthesis and characterization data of 
compounds 6-8, 10, 12-18, 20-42, HPLC-MS purity analyses of final compounds 6-41, and molecular 
formula strings for compounds 1-48. This material is available free of charge via the Internet at 
http://pubs.acs.org. 
 
ACKNOWLEDGEMENTS 
This work was supported by grants from MINECO (SAF2013-48271-C2, SAF2014-57138-C2-2-R, 
SAF2016-78792-R and INNPACTO 01/12-CL-0-12-09), CAM (S2010/BMD2353), Xunta de Galicia 
(GRC2014/011), Junta de Andalucía (CTS-8221 and CTS-433), and European Regional Development 
Fund (ERDF). J.G.-C. is grateful to MINECO for a predoctoral fellowship. The authors thank the NMR 
Core Facilities from Universidad Complutense de Madrid. 
 
Page 17 of 32
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 AUTHOR INFORMATION 
Corresponding Author 
*M.L.L.-R.: phone, 34 91 3944239; e-mail: mluzlr@ucm.es. F.R.F.: phone, 34 952 614 012; e-mail: 
fernando.rodriguez@ibima.eu 
Author Contributions 
∆ These authors share first authorship of this work. 
 
ABBREVIATIONS 
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 Scheme 1.
a Synthesis of target compounds 6-14. 
 
 
a Reagents and conditions: (a) amino N-heterocycle, NaBH(OAc)3, 1,2-dichloroethane, ∆, 
8-15 h, 11-21% (6-9, 13); (b) i) amino N-heterocycle, p-TSA, toluene, ∆, 5-18 h; ii) NaBH4, 
MeOH, 0 °C to rt, 1-2 h, 33-73% (10-12, 14). 
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 Scheme 2.
a Synthesis of target compounds 15–41. 
 
 
a Reagents and conditions: (a) i) pyridin-3-amine, p-TSA, toluene, ∆, 1-6 h; ii) NaBH4, 
MeOH, 0 °C to rt, 15-60 min, 26-91%; (b) benzyl bromide derivative, NaH, DMF, rt, 15 min, 
30-87%; (c) 2-, 3- or 4-(bromomethyl)pyridine hydrobromide, Cs2CO3, DMF, rt, 2 h, 86-94%; 
(d) (bromomethyl)cyclopropane, NaH, DMF, rt, 1 h, 97%. 
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 Table 1. Effect of identified hit 5 and new compounds 6-14 in 5-HT-induced IP 
production in 5-HT2CR-HeLa cells. 
 
compd N-heterocycle potentiation 
5 
N N
 
20±4 
6 N
N
 
0 
7 N N
 
0 
8 N
N
 
0 
9 N
N
 
9±3 
10 
N
N
 
0 
11 
N
 
35±5 
12 N
 
25±3 
13 
N
 
0 
14 
N
 
21±4 
a Potentiation of 5-HT Emax at a fixed 
concentration of compound = 10 µM; 
values are the mean±SEM of three 
independent experiments with duplicate 
determinations. 
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 Table 2. Effect of selected compound 11 and new compounds 15-41 in 5-HT-induced IP 
production in 5-HT2CR-HeLa cells. 
 
compd R Potentiationa compd R 
Potentiation
a 
11 
 
35±5 28 
 
7±3 
15 
F 
9±2 29 
O  
6±2 
16 
F
 
22±3 30 
O
 
0 
17 
F
 
6±1 31 
O
 
0 
18 
Cl  
13±3 32 
CF3  
8±4 
19 
Cl
 
26±4 33 
CF3
 
0 
20 
Cl
 
7±2 34 
CF3
 
9±3 
21 
Br  
6±2 35 
CN  
7±2 
22 
Br
 
7±3 36 
CN
 
22±2 
23 
Br
 
0 37 
CN
 
7±4 
24 
F
F
 
9±1 38 
N 
9±3 
25 
Cl
F
 
9±2 39 N
 
25±3 
26 
 
24±2 40 
N
 
0 
27  
27±3 41  0 
a Potentiation of 5-HT Emax at a fixed concentration of 
compound = 10 µM; values are the mean±SEM of three 
independent experiments with duplicate determinations. 
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Figure 1. (A) Classical serotoninergic anti-obesity agents. (B) 5-HT2CR ligands: agonist 3 
clinically used for obesity and positive allosteric modulator 4. 
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Figure 2. High-throughput screening of Vivia Biotech chemical library and subsequent 
functional validation allowed to identify hit compound 5 which entered a medicinal chemistry 
program for the search of allosteric modulators of the 5-HT2CR. 
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Figure 3. In vitro characterization of compound 11. (A) 5-HT curves in the presence of 
increasing concentrations of the compound. (B) Effect of the compound in the absence of 
serotonin. (C) Allosteric effect of the compound at the 5-HT2AR. (D) Agonist effect of the 
compound at the 5-HT2AR. (E) Allosteric effect of the compound at the 5-HT2BR. (F) Agonist 
effect of the compound at the 5-HT2BR. (G) Binding displacements of orthosteric ligands of 
the 5-HT2CR by 10 µM 11. Points represent the mean ± SD (vertical bars) of triplicate 
measurements. 
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Figure 4. In vivo behaviour of the new 5-HT2CR PAM 11. (A) The 5-HT2CR agonist 47 
reduced feeding in food deprived animals. (B) In a similar model, compound 11 has a more 
potent and prolonged action. (C) When administered in animals with restricted food access (4 
h / day), 11 reduced daily feeding. (D) This effect was also observed when the compound was 
given to animals with continuous access to food. (E,F) In both models —food restriction and 
continuous access—, repeated administration of 11 reduced net body weight gain. (G) 
Compound 11 induced hypolocomotion in the elevated plus maze. (H) Compound 11 did not 
result in conditioned taste aversion. * denotes statistical significance (P<0.01) when compared 
to control. N = at least 8 animals per group. 
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Figure 5. In vivo allosteric modulation of serotonin-induced feeding suppression by 
compound 11. (A) Selective serotonin re-uptake inhibitor sertraline induced a mild feeding 
suppression in rats. (B,C) When the extracellular concentration of serotonin increased upon 
administration of sertraline, the anorectic effect of 11 was potentiated. * denotes statistical 
significance (P<0.01) when compared to control. N = at least 8 animals per group. 
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